Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10418779 | 0.75 | HTR2A (0.34) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL31716197 | 0.72 | CUL4A (0.35) | KDM1A | |
| SCHEMBL7312928 | 0.72 | ALDH1A1 (0.36) | KDM1A | |
| SCHEMBL20520159 | 0.69 | KDM1A (0.33) | KDM1A | |
| SCHEMBL16428784 | 0.69 | ALDH1A1 (0.33) | KDM1A | |
| SCHEMBL3728489 | 0.69 | — | — | |
| SCHEMBL9842972 | 0.68 | — | — | |
| SCHEMBL1863590 | 0.67 | — | — | |
| SCHEMBL734440 | 0.66 | KDM1A (0.38) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL20017698 | 0.66 | HTR2A (0.35) | KDM1AHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271246-A | Method for continuously preparing 2-butyl-1, 3-diazaspiro [4.4] nonane-1-en-4-one | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-118271246-A | Method for continuously preparing 2-butyl-1, 3-diazaspiro [4.4] nonane-1-en-4-one | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-115215813-A | Method for controlling valsartan impurity | 江苏新瑞药业有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-102145297-A | Solid acid catalyst and method for catalytic synthesis of 5-substituted tetrazole by solid acid catalyst | ZHEJIANG KINGLYUAN PHARMACEUTICAL COMPANY LTD | 2011-08-10 | — | — | CN | disclosed |
| EP-1019048-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | Merck Sharp Dohme (Italia) S.P.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999016437-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME (ITALIA) S.P.A. (IT) | 1999-04-08 | — | — | WO | disclosed |